Yersinia enterocolitica

Cell death is essential to your health − an immunologist explains when cells decide to die with a bang or take their quiet leave

Retrieved on: 
Mittwoch, Oktober 4, 2023
Apoptosis, Tissue, Infection, Endometriosis, DNA, Maintenance, Yersinia enterocolitica, Cell death, DSM-IV codes, Neoplasm, Black, COVID-19, Fever, Finger, Survival, Cancer, The, Black Death, Research, Cell, Lupus, Yersinia pestis, Uterus, Pain, Pandemic, Protein, Patient, Swelling, Immune system, Bacteria, Immunodeficiency, Health, Death, Yersinia, Virus, Red, Skin, Vaccine, Pharmaceutical industry

While death may seem passive, an unfortunate ending that just “happens,” the death of your cells is often extremely purposeful and strategic.

Key Points: 
  • While death may seem passive, an unfortunate ending that just “happens,” the death of your cells is often extremely purposeful and strategic.
  • The intricate details of how and why cells die can have significant effects on your overall health.
  • My own research explores how immune cells switch between different types of programmed death in scenarios like cancer or injury.

Quietly exiting: silent cell death

    • Regardless of the timeline, the death of old and damaged cells and their replacement with new cells is a normal and important bodily process.
    • Silent cell death, or apoptosis, is described as silent because these cells die without causing an inflammatory reaction.
    • Apoptosis is an active process involving many proteins and switches within the cell.
    • Sometimes cells can detect that their own functions are failing and turn on executioner proteins that chop up their own DNA, and they quietly die by apoptosis.
    • Whether it’s for development or maintenance, your cells are quietly exiting to keep your body happy and healthy.

Going out with a bang: inflammatory cell death

    • This inflammatory cell death is typically triggered by bacteria, viruses or stress.
    • Rather than quietly shutting down, cells undergoing inflammatory cell death will make themselves burst, or lyse, killing themselves and exploding inflammatory messengers as they go.
    • These infections are rarely fatal because your immune cells can aggressively eliminate the pathogen’s niche by inducing inflammatory cell death.
    • The virus behind the COVID-19 pandemic also causes a lot of inflammatory cell death.
    • Researchers are still studying the role of inflammatory cell death in COVID-19 infection, and understanding this delicate balance can help improve treatments.

Molecular Designs releases their new Simplicity™ Gastrointestinal Pathogen Panel

Retrieved on: 
Dienstag, April 11, 2023
GMP, STEC, Yersinia enterocolitica, Clostridioides difficile, ISO, Molecular design software, ETEC, Research, Escherichia coli, Entamoeba histolytica, Rotavirus, Giardia duodenalis, Dicarboxylic acid, EIEC, Polymerase chain reaction, Laboratory, Adenoviridae, GI, PCR, Pharmaceutical industry, Campylobacter

BIRMINGHAM, Ala., April 11, 2023 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays , announces the release of its new Simplicity™ Gastrointestinal Pathogen Panel for the detection of causative agents of gastrointestinal (GI) tract infections.

Key Points: 
  • BIRMINGHAM, Ala., April 11, 2023 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays , announces the release of its new Simplicity™ Gastrointestinal Pathogen Panel for the detection of causative agents of gastrointestinal (GI) tract infections.
  • The GI panel is a multiplex PCR assay that identifies nucleic acids from 16 different organisms, from a single sample.
  • Molecular Designs assays are manufactured to GMP and ISO 13485:2016 standards and are compatible with most PCR platforms.
  • "Our Simplicity Gastrointestinal Pathogen Panel is available to reference and hospital laboratories," said Robert Crisp , Ph.D., Vice President of Research & Development at Molecular Designs.

Microba Launches Next Generation Healthcare Testing

Retrieved on: 
Dienstag, Februar 28, 2023
Medical Supplies, Biotechnology, Health, General Health, Pharmaceutical, Other Science, Medical Devices, Research, Infectious Diseases, Science, Clinical Trials, Parasitism, Bacteria, Cyclospora cayetanensis, Yersinia enterocolitica, Annual report, Lactoferrin, Fungus, Butyric acid, Methane, ASX, File association, Lipopolysaccharide, Giardia duodenalis, Immunoglobulin A, Health professional, TMA, Pancreatic elastase, Stool test, Entamoeba histolytica, Microorganism, Completeness, IPA, BCAA, Multimedia, MAP, Diagnosis, Pharmaceutical industry, Antibiotics, Blastocystis

Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.

Key Points: 
  • Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.
  • The MetaXplore™ test range has been developed together with healthcare professionals and brought to market under a new brand called Co-Biome™.
  • The MetaXplore™ test range through Co-Biome™ represents an important step forward in that strategy by breaking new ground in the application of microbiome testing in healthcare.
  • Microba’s Chief Scientific Officer, Assoc Prof. Lutz Krause said, “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting.

Hardy Diagnostics Now Offers the BioCode® MDx-3000

Retrieved on: 
Montag, März 14, 2022
Federal Food, Drug, and Cosmetic Act, Gram, Partnership, NL63, Laboratory, RPP, OC43, STEC, Campylobacter, Hair, BMB, Emergency Use Authorization, Severe acute respiratory syndrome coronavirus 2, Bacteria, Stanford University v. Roche Molecular Systems, Inc., Hardy, Escherichia coli, Hardy Diagnostics, Allergy, FDA, EIEC, EUA, Infection, EAEC, GLOBE, Hematology, Autoimmune disease, LIS, Microbiology, ETEC, PCR, Automation, 1993 Jack in the Box E. coli outbreak, RSV, Vibrio parahaemolyticus, Culture, GPP, Immunochemistry, Nomenclature codes, IVD, Fungus, Medical degree, Molecular Probes, Yersinia enterocolitica, Virus, COVID, HKU1, Laboratory information management system, CE marking, Hospital, Technology, COVID-19, Diagnosis, Vaccine, Medical device, Coronavirus

"Applied BioCode is thrilled to partner with Hardy Diagnostics," said Winston Ho, President of Applied BioCode.

Key Points: 
  • "Applied BioCode is thrilled to partner with Hardy Diagnostics," said Winston Ho, President of Applied BioCode.
  • "We look forward to working with the Hardy Diagnostics team to expand our reach in hospitals and reference laboratories in the US."
  • Hardy Diagnostics is an FDA-licensed manufacturer of medical devices for microbiology testing with an ISO 13485 certified Quality Management System.
  • Hardy Diagnostics distributes more than 13,000 products, services more than 10,000 laboratories and exports to more than 80 foreign distributors.